SCHEMBL7017763

SCHEMBL7017763

O=S(=O)(CC1CC1)c1ccc(CBr)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 1/20 0.41
MMP2 P08253 7/20 0.39
MMP9 P14780 7/20 0.39
MMP14 P50281 7/20 0.39
MMP8 P22894 6/20 0.39
MMP3 P08254 2/20 0.39
MMP7 P09237 2/20 0.39
KCNH2 Q12809 1/20 0.39
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
AOC2 O75106 1/20 0.38
PSIP1 O75475 1/20 0.37
PLCG1 P19174 1/20 0.36
CRBN Q96SW2 3/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507371 0.91 KCNH2 (0.39) GLP1RMMP2MMP9MMP14MMP8
SCHEMBL18275082 0.81 PSIP1 (0.60) GLP1RMMP2MMP9MMP14MMP8
SCHEMBL2413925 0.80 PLCG1 (0.59) MMP2MMP9MMP8MAOAMAOB
SCHEMBL30026070 0.78 CA12 (0.56) GLP1RMMP2MMP9MMP14MMP8
SCHEMBL20931314 0.78 CA2 (0.55) GLP1RMMP2MMP9MMP14MMP8
SCHEMBL16799853 0.77 CA2 (0.46) MMP9ALDH1A1GAACA2
SCHEMBL18275216 0.76 GLP1R (0.34) GLP1RKCNH2PSEN1PSEN2APH1B
SCHEMBL2536571 0.76 MAOA (0.40) GLP1RMMP2MMP9MMP14MMP8
SCHEMBL4595077 0.76 CRBN (0.55) MMP2MMP9MMP14MMP8MMP3
SCHEMBL1782820 0.76 CRBN (0.55) CRBNALDH1A1GAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 GLP1R 3668/4885MMP2 16/4885MMP9 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.